December 7th 2019
Enrique Grande, MD, discusses the rationale of the IMvigor130 trial in urothelial cancer.
October 17th 2019
Enrique Grande, MD, discusses the design of the phase III IMvigor130 trial, which compared atezolizumab plus chemotherapy versus atezolizumab monotherapy (arm B) versus standard chemotherapy plus placebo in patients with previously untreated locally advanced or metastatic urothelial carcinoma.
End of data